Humacyte, Inc. Cash Flow Statement
HUMA|1 years of annual SEC 10-K data (FY2025-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
Humacyte, Inc. used $98M in operating cash flow and negative free cash flow of $100M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.88 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 |
|---|---|
| Net Income | -$148.7M |
| Depreciation & Amortization | $5.1M |
| Operating Cash Flow | -$98.1M |
| Capital Expenditures | $1.6M |
| Free Cash Flow | -$99.7M |